未登录

C

Charles Oo

sunlife biopharma

H指数:18

被引数:1,068

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?

治疗性生物制剂的监管批准：与小型分子相比，是持续进步还是趋于平缓？

Drug Discovery Today

IF7.5

2025-10-240

PRE

Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?

DRUG DISCOVERY TODAY

IF7.5

2023-08-012

PRE

Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2023-06-015

OA

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

FRONTIERS IN MICROBIOLOGY

IF4.5

2022-11-226

OAAI

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii

FRONTIERS IN MICROBIOLOGY

IF4.5

2022-09-2313

OAAI

Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic

DRUG DISCOVERY TODAY

IF7.5

2021-06-010

OAAI

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective

DRUG DISCOVERY TODAY

IF7.5

2020-01-0112

PREAI

Fixed-dose combinations: a potential means to boost drug development for selected drugs

DRUG DISCOVERY TODAY

IF7.5

2018-03-0113

PREAI

Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

EXPERT REVIEW OF CLINICAL PHARMACOLOGY

IF3

2016-03-1630

OAAI

There is no better time than the present: nanotechnology as a disruptive innovation for drug development

DRUG DISCOVERY TODAY

IF7.5

2015-06-014

PREAI

Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2014-01-100

PREAI

A Feasibility Study of Differential Delivery of Levodopa Ester and Benserazide Using Site-Specific Intestinal Loops in Rats

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2010-01-013

PREAI

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2003-05-0135

PREAI

Safety and pharmacology of oseltamivir in clinical use

IF3.8

2003-01-0194

OA

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

口服抗流感神经氨酸酶抑制剂前药奥司他韦和抗酸剂之间缺乏药代动力学相互作用

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2002-10-2324

OAAI

Change in creatinine clearance with advancing age

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

IF4.5

2002-10-174

OAAI

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2002-06-0121

OAAI

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2000-10-0178

OAAI

Lack of effect of orlistat on the pharmacokinetics and pharmacodynamics of pravastatin.

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

1999-02-011

PREAI